Φάσεις κλινικών δοκιμών (Greek Wikipedia)

Analysis of information sources in references of the Wikipedia article "Φάσεις κλινικών δοκιμών" in Greek language version.

refsWebsite

Global rank Greek rank

15doi.org

2^nd place

3^rd place

10worldcat.org

5^th place

8^th place

4nih.gov

4^th place

2fda.gov

447^th place

368^th place

2nature.com

234^th place

207^th place

1imop.gr

low place

5,579^th place

1elsevier.com

610^th place

447^th place

1eof.gr

low place

1pharmaceutical-journal.com

low place

9,442^nd place

1medcitynews.com

low place

1bio.org

low place

1web.archive.org

1^st place

1europa.eu

68^th place

24^th place

1sciencedirect.com

149^th place

206^th place

1technewslit.com

low place

1inserm.fr

9,568^th place

low place

1recoverytrial.net

low place

1mit.edu

415^th place

412^th place

1cancer.org

3,680^th place

2,849^th place

1commercialbiotechnology.com

low place

1healthaffairs.org

low place

bio.org

«Clinical Development Success Rates 2006-2015» (PDF). Ανακτήθηκε στις 11 Ιουλίου 2021.

cancer.org

«Types and Phases of Clinical Trials | What Are Clinical Trial Phases?». www.cancer.org (στα Αγγλικά). Ανακτήθηκε στις 11 Ιουλίου 2021.

commercialbiotechnology.com

Holland, John (2013-01-01). «Fixing a broken drug development process» (στα αγγλικά). Journal of Commercial Biotechnology 19 (1). doi:10.5912/jcb588. ISSN 1478-565X. http://commercialbiotechnology.com/index.php/jcb/article/view/588.

doi.org

dx.doi.org

The Lancet (2009-07). «Phase 0 trials: a platform for drug development?» (στα English). The Lancet 374 (9685): 176. doi:10.1016/S0140-6736(09)61309-X. ISSN 0140-6736. https://linkinghub.elsevier.com/retrieve/articleSelectPrefsTemp?Redirect=http://www.thelancet.com/retrieve/pii/S014067360961309X&key=b5a9f2377992503bfdf3f649a4bea02138f97e66.
Burt, Tal; Young, Graeme; Lee, Wooin; Kusuhara, Hiroyuki; Langer, Oliver; Rowland, Malcolm; Sugiyama, Yuichi (2020-11). «Phase 0/microdosing approaches: time for mainstream application in drug development?» (στα αγγλικά). Nature Reviews Drug Discovery 19 (11): 801–818. doi:10.1038/s41573-020-0080-x. ISSN 1474-1784. https://www.nature.com/articles/s41573-020-0080-x.
Yuan, Jiacheng; Pang, Herbert; Tong, Tiejun; Xi, Dong; Guo, Wenzhao; Mesenbrink, Peter (2016-09-02). «Seamless Phase IIa/IIb and enhanced dose-finding adaptive design». Journal of Biopharmaceutical Statistics 26 (5): 912–923. doi:10.1080/10543406.2015.1094807. ISSN 1054-3406. PMID 26390951. PMC PMC5025390. https://doi.org/10.1080/10543406.2015.1094807.
«Phase II Trials in Drug Development and Adaptive Trial Design» (στα αγγλικά). JACC: Basic to Translational Science 4 (3): 428–437. 2019-06-01. doi:10.1016/j.jacbts.2019.02.005. ISSN 2452-302X. https://www.sciencedirect.com/science/article/pii/S2452302X19300658.
Pallmann, Philip; Bedding, Alun W.; Choodari-Oskooei, Babak; Dimairo, Munyaradzi; Flight, Laura; Hampson, Lisa V.; Holmes, Jane; Mander, Adrian P. και άλλοι. (2018-02-28). «Adaptive designs in clinical trials: why use them, and how to run and report them». BMC Medicine 16 (1): 29. doi:10.1186/s12916-018-1017-7. ISSN 1741-7015. PMID 29490655. PMC PMC5830330. https://doi.org/10.1186/s12916-018-1017-7.
Lo, Andrew W.; Siah, Kien Wei; Wong, Chi Heem (2020-05-14). «Estimating Probabilities of Success of Vaccine and Other Anti-Infective Therapeutic Development Programs» (στα αγγλικά). Harvard Data Science Review. doi:10.1162/99608f92.e0c150e8. https://hdsr.mitpress.mit.edu/pub/pnp0pr4j/release/1.
Wong, Chi Heem; Siah, Kien Wei; Lo, Andrew W (2019-04-01). «Estimation of clinical trial success rates and related parameters». Biostatistics 20 (2): 273–286. doi:10.1093/biostatistics/kxx069. ISSN 1465-4644. https://doi.org/10.1093/biostatistics/kxx069.
Arrowsmith, John (2011-02-01). «Phase III and submission failures: 2007–2010» (στα αγγλικά). Nature Reviews Drug Discovery 10 (2): 87–87. doi:10.1038/nrd3375. ISSN 1474-1784. https://www.nature.com/articles/nrd3375.
Sertkaya, Aylin; Wong, Hui-Hsing; Jessup, Amber; Beleche, Trinidad (2016-04-01). «Key cost drivers of pharmaceutical clinical trials in the United States» (στα αγγλικά). Clinical Trials 13 (2): 117–126. doi:10.1177/1740774515625964. ISSN 1740-7745. https://doi.org/10.1177/1740774515625964.
Holland, John (2013-01-01). «Fixing a broken drug development process» (στα αγγλικά). Journal of Commercial Biotechnology 19 (1). doi:10.5912/jcb588. ISSN 1478-565X. http://commercialbiotechnology.com/index.php/jcb/article/view/588.
Adams, Christopher P.; Brantner, Van V. (2006-03-01). «Estimating The Cost Of New Drug Development: Is It Really $802 Million?». Health Affairs 25 (2): 420–428. doi:10.1377/hlthaff.25.2.420. ISSN 0278-2715. https://www.healthaffairs.org/doi/10.1377/hlthaff.25.2.420.

doi.org

Yuan, Jiacheng; Pang, Herbert; Tong, Tiejun; Xi, Dong; Guo, Wenzhao; Mesenbrink, Peter (2016-09-02). «Seamless Phase IIa/IIb and enhanced dose-finding adaptive design». Journal of Biopharmaceutical Statistics 26 (5): 912–923. doi:10.1080/10543406.2015.1094807. ISSN 1054-3406. PMID 26390951. PMC PMC5025390. https://doi.org/10.1080/10543406.2015.1094807.
Pallmann, Philip; Bedding, Alun W.; Choodari-Oskooei, Babak; Dimairo, Munyaradzi; Flight, Laura; Hampson, Lisa V.; Holmes, Jane; Mander, Adrian P. και άλλοι. (2018-02-28). «Adaptive designs in clinical trials: why use them, and how to run and report them». BMC Medicine 16 (1): 29. doi:10.1186/s12916-018-1017-7. ISSN 1741-7015. PMID 29490655. PMC PMC5830330. https://doi.org/10.1186/s12916-018-1017-7.
Wong, Chi Heem; Siah, Kien Wei; Lo, Andrew W (2019-04-01). «Estimation of clinical trial success rates and related parameters». Biostatistics 20 (2): 273–286. doi:10.1093/biostatistics/kxx069. ISSN 1465-4644. https://doi.org/10.1093/biostatistics/kxx069.
Sertkaya, Aylin; Wong, Hui-Hsing; Jessup, Amber; Beleche, Trinidad (2016-04-01). «Key cost drivers of pharmaceutical clinical trials in the United States» (στα αγγλικά). Clinical Trials 13 (2): 117–126. doi:10.1177/1740774515625964. ISSN 1740-7745. https://doi.org/10.1177/1740774515625964.

elsevier.com

linkinghub.elsevier.com

The Lancet (2009-07). «Phase 0 trials: a platform for drug development?» (στα English). The Lancet 374 (9685): 176. doi:10.1016/S0140-6736(09)61309-X. ISSN 0140-6736. https://linkinghub.elsevier.com/retrieve/articleSelectPrefsTemp?Redirect=http://www.thelancet.com/retrieve/pii/S014067360961309X&key=b5a9f2377992503bfdf3f649a4bea02138f97e66.

eof.gr

«Εθνικός Οργανισμός Φαρμάκων - Δράση». www.eof.gr. Ανακτήθηκε στις 11 Ιουλίου 2021.

europa.eu

ema.europa.eu

«Human medicines: regulatory information». Αρχειοθετήθηκε από το πρωτότυπο στις 10 Ιουλίου 2021. Ανακτήθηκε στις 11 Ιουλίου 2021.

fda.gov

Commissioner, Office of the (20 Φεβρουαρίου 2020). «The Drug Development Process». FDA (στα Αγγλικά). Ανακτήθηκε στις 28 Φεβρουαρίου 2021.
Commissioner, Office of the (2019-04-18). «Step 3: Clinical Research» (στα αγγλικά). FDA. https://www.fda.gov/patients/drug-development-process/step-3-clinical-research.

healthaffairs.org

Adams, Christopher P.; Brantner, Van V. (2006-03-01). «Estimating The Cost Of New Drug Development: Is It Really $802 Million?». Health Affairs 25 (2): 420–428. doi:10.1377/hlthaff.25.2.420. ISSN 0278-2715. https://www.healthaffairs.org/doi/10.1377/hlthaff.25.2.420.

imop.gr

«Γνωριμία με τις Kλινικές Mελέτες | ΙΜΟΠ». www.imop.gr. Ανακτήθηκε στις 11 Ιουλίου 2021.

inserm.fr

presse.inserm.fr

«Launch of a European clinical trial against COVID-19». Newsroom | Inserm (στα Αγγλικά). 22 Μαρτίου 2020. Ανακτήθηκε στις 11 Ιουλίου 2021.

medcitynews.com

HEALTH, Highlight (2 Ιουνίου 2011). «New drugs failing Phase II and III clinical trials». MedCity News (στα Αγγλικά). Ανακτήθηκε στις 11 Ιουλίου 2021.

mit.edu

hdsr.mitpress.mit.edu

Lo, Andrew W.; Siah, Kien Wei; Wong, Chi Heem (2020-05-14). «Estimating Probabilities of Success of Vaccine and Other Anti-Infective Therapeutic Development Programs» (στα αγγλικά). Harvard Data Science Review. doi:10.1162/99608f92.e0c150e8. https://hdsr.mitpress.mit.edu/pub/pnp0pr4j/release/1.

nature.com

Burt, Tal; Young, Graeme; Lee, Wooin; Kusuhara, Hiroyuki; Langer, Oliver; Rowland, Malcolm; Sugiyama, Yuichi (2020-11). «Phase 0/microdosing approaches: time for mainstream application in drug development?» (στα αγγλικά). Nature Reviews Drug Discovery 19 (11): 801–818. doi:10.1038/s41573-020-0080-x. ISSN 1474-1784. https://www.nature.com/articles/s41573-020-0080-x.
Arrowsmith, John (2011-02-01). «Phase III and submission failures: 2007–2010» (στα αγγλικά). Nature Reviews Drug Discovery 10 (2): 87–87. doi:10.1038/nrd3375. ISSN 1474-1784. https://www.nature.com/articles/nrd3375.

nih.gov

ncbi.nlm.nih.gov

Yuan, Jiacheng; Pang, Herbert; Tong, Tiejun; Xi, Dong; Guo, Wenzhao; Mesenbrink, Peter (2016-09-02). «Seamless Phase IIa/IIb and enhanced dose-finding adaptive design». Journal of Biopharmaceutical Statistics 26 (5): 912–923. doi:10.1080/10543406.2015.1094807. ISSN 1054-3406. PMID 26390951. PMC PMC5025390. https://doi.org/10.1080/10543406.2015.1094807.
Pallmann, Philip; Bedding, Alun W.; Choodari-Oskooei, Babak; Dimairo, Munyaradzi; Flight, Laura; Hampson, Lisa V.; Holmes, Jane; Mander, Adrian P. και άλλοι. (2018-02-28). «Adaptive designs in clinical trials: why use them, and how to run and report them». BMC Medicine 16 (1): 29. doi:10.1186/s12916-018-1017-7. ISSN 1741-7015. PMID 29490655. PMC PMC5830330. https://doi.org/10.1186/s12916-018-1017-7.

pubmedcentral.nih.gov

Yuan, Jiacheng; Pang, Herbert; Tong, Tiejun; Xi, Dong; Guo, Wenzhao; Mesenbrink, Peter (2016-09-02). «Seamless Phase IIa/IIb and enhanced dose-finding adaptive design». Journal of Biopharmaceutical Statistics 26 (5): 912–923. doi:10.1080/10543406.2015.1094807. ISSN 1054-3406. PMID 26390951. PMC PMC5025390. https://doi.org/10.1080/10543406.2015.1094807.
Pallmann, Philip; Bedding, Alun W.; Choodari-Oskooei, Babak; Dimairo, Munyaradzi; Flight, Laura; Hampson, Lisa V.; Holmes, Jane; Mander, Adrian P. και άλλοι. (2018-02-28). «Adaptive designs in clinical trials: why use them, and how to run and report them». BMC Medicine 16 (1): 29. doi:10.1186/s12916-018-1017-7. ISSN 1741-7015. PMID 29490655. PMC PMC5830330. https://doi.org/10.1186/s12916-018-1017-7.

pharmaceutical-journal.com

Torjesen, Ingrid. «Drug development: the journey of a medicine from lab to shelf». The Pharmaceutical Journal (στα Αγγλικά). Ανακτήθηκε στις 11 Ιουλίου 2021.

recoverytrial.net

«Welcome — RECOVERY Trial». www.recoverytrial.net. Ανακτήθηκε στις 11 Ιουλίου 2021.

sciencedirect.com

«Phase II Trials in Drug Development and Adaptive Trial Design» (στα αγγλικά). JACC: Basic to Translational Science 4 (3): 428–437. 2019-06-01. doi:10.1016/j.jacbts.2019.02.005. ISSN 2452-302X. https://www.sciencedirect.com/science/article/pii/S2452302X19300658.

technewslit.com

sciencebusiness.technewslit.com

Alan. «WHO Beginning Covid-19 Therapy Trial « Science and Enterprise». sciencebusiness.technewslit.com (στα Αγγλικά). Ανακτήθηκε στις 11 Ιουλίου 2021.

web.archive.org

«Human medicines: regulatory information». Αρχειοθετήθηκε από το πρωτότυπο στις 10 Ιουλίου 2021. Ανακτήθηκε στις 11 Ιουλίου 2021.

worldcat.org

The Lancet (2009-07). «Phase 0 trials: a platform for drug development?» (στα English). The Lancet 374 (9685): 176. doi:10.1016/S0140-6736(09)61309-X. ISSN 0140-6736. https://linkinghub.elsevier.com/retrieve/articleSelectPrefsTemp?Redirect=http://www.thelancet.com/retrieve/pii/S014067360961309X&key=b5a9f2377992503bfdf3f649a4bea02138f97e66.
Burt, Tal; Young, Graeme; Lee, Wooin; Kusuhara, Hiroyuki; Langer, Oliver; Rowland, Malcolm; Sugiyama, Yuichi (2020-11). «Phase 0/microdosing approaches: time for mainstream application in drug development?» (στα αγγλικά). Nature Reviews Drug Discovery 19 (11): 801–818. doi:10.1038/s41573-020-0080-x. ISSN 1474-1784. https://www.nature.com/articles/s41573-020-0080-x.
Yuan, Jiacheng; Pang, Herbert; Tong, Tiejun; Xi, Dong; Guo, Wenzhao; Mesenbrink, Peter (2016-09-02). «Seamless Phase IIa/IIb and enhanced dose-finding adaptive design». Journal of Biopharmaceutical Statistics 26 (5): 912–923. doi:10.1080/10543406.2015.1094807. ISSN 1054-3406. PMID 26390951. PMC PMC5025390. https://doi.org/10.1080/10543406.2015.1094807.
«Phase II Trials in Drug Development and Adaptive Trial Design» (στα αγγλικά). JACC: Basic to Translational Science 4 (3): 428–437. 2019-06-01. doi:10.1016/j.jacbts.2019.02.005. ISSN 2452-302X. https://www.sciencedirect.com/science/article/pii/S2452302X19300658.
Pallmann, Philip; Bedding, Alun W.; Choodari-Oskooei, Babak; Dimairo, Munyaradzi; Flight, Laura; Hampson, Lisa V.; Holmes, Jane; Mander, Adrian P. και άλλοι. (2018-02-28). «Adaptive designs in clinical trials: why use them, and how to run and report them». BMC Medicine 16 (1): 29. doi:10.1186/s12916-018-1017-7. ISSN 1741-7015. PMID 29490655. PMC PMC5830330. https://doi.org/10.1186/s12916-018-1017-7.
Wong, Chi Heem; Siah, Kien Wei; Lo, Andrew W (2019-04-01). «Estimation of clinical trial success rates and related parameters». Biostatistics 20 (2): 273–286. doi:10.1093/biostatistics/kxx069. ISSN 1465-4644. https://doi.org/10.1093/biostatistics/kxx069.
Arrowsmith, John (2011-02-01). «Phase III and submission failures: 2007–2010» (στα αγγλικά). Nature Reviews Drug Discovery 10 (2): 87–87. doi:10.1038/nrd3375. ISSN 1474-1784. https://www.nature.com/articles/nrd3375.
Sertkaya, Aylin; Wong, Hui-Hsing; Jessup, Amber; Beleche, Trinidad (2016-04-01). «Key cost drivers of pharmaceutical clinical trials in the United States» (στα αγγλικά). Clinical Trials 13 (2): 117–126. doi:10.1177/1740774515625964. ISSN 1740-7745. https://doi.org/10.1177/1740774515625964.
Holland, John (2013-01-01). «Fixing a broken drug development process» (στα αγγλικά). Journal of Commercial Biotechnology 19 (1). doi:10.5912/jcb588. ISSN 1478-565X. http://commercialbiotechnology.com/index.php/jcb/article/view/588.
Adams, Christopher P.; Brantner, Van V. (2006-03-01). «Estimating The Cost Of New Drug Development: Is It Really $802 Million?». Health Affairs 25 (2): 420–428. doi:10.1377/hlthaff.25.2.420. ISSN 0278-2715. https://www.healthaffairs.org/doi/10.1377/hlthaff.25.2.420.